دورية أكاديمية
Tafenoquine-Atovaquone Combination Achieves Radical Cure and Confers Sterile Immunity in Experimental Models of Human Babesiosis.
| العنوان: | Tafenoquine-Atovaquone Combination Achieves Radical Cure and Confers Sterile Immunity in Experimental Models of Human Babesiosis. |
|---|---|
| المؤلفون: | Vydyam P; Department of Infectious Diseases, School of Medicine, Yale University, New Haven, Connecticut, USA., Pal AC; Department of Infectious Diseases, School of Medicine, Yale University, New Haven, Connecticut, USA., Renard I; Department of Infectious Diseases, School of Medicine, Yale University, New Haven, Connecticut, USA., Chand M; Department of Infectious Diseases, School of Medicine, Yale University, New Haven, Connecticut, USA., Kumari V; Department of Infectious Diseases, School of Medicine, Yale University, New Haven, Connecticut, USA., Gennaro JC; Department of Infectious Diseases, School of Medicine, Yale University, New Haven, Connecticut, USA., Mamoun CB; Department of Infectious Diseases, School of Medicine, Yale University, New Haven, Connecticut, USA. |
| المصدر: | The Journal of infectious diseases [J Infect Dis] 2024 Jan 12; Vol. 229 (1), pp. 161-172. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Jan. 2011- : Oxford : Oxford University Press Original Publication: 1904-2010 : Chicago, IL : University of Chicago Press |
| مواضيع طبية MeSH: | Babesiosis* , Babesia* , Aminoquinolines*, Humans ; Animals ; Mice ; Atovaquone/pharmacology ; Atovaquone/therapeutic use ; Models, Theoretical |
| مستخلص: | Human babesiosis is a potentially fatal tick-borne disease caused by intraerythrocytic Babesia parasites. The emergence of resistance to recommended therapies highlights the need for new and more effective treatments. Here we demonstrate that the 8-aminoquinoline antimalarial drug tafenoquine inhibits the growth of different Babesia species in vitro, is highly effective against Babesia microti and Babesia duncani in mice and protects animals from lethal infection caused by atovaquone-sensitive and -resistant B. duncani strains. We further show that a combination of tafenoquine and atovaquone achieves cure with no recrudescence in both models of human babesiosis. Interestingly, elimination of B. duncani infection in animals following drug treatment also confers immunity to subsequent challenge. Altogether, the data demonstrate superior efficacy of tafenoquine plus atovaquone combination over current therapies for the treatment of human babesiosis and highlight its potential in providing protective immunity against Babesia following parasite clearance. Competing Interests: Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.) |
| References: | Int J Parasitol. 2019 Feb;49(2):165-174. (PMID: 30690090) Pathogens. 2021 Sep 01;10(9):. (PMID: 34578153) MMWR Morb Mortal Wkly Rep. 2023 Mar 17;72(11):273-277. (PMID: 36928071) Cureus. 2022 Mar 20;14(3):e23344. (PMID: 35475076) Clin Infect Dis. 2017 Oct 1;65(7):1222-1225. (PMID: 28541469) BMC Med. 2017 Sep 13;15(1):168. (PMID: 28903777) Drugs. 2018 Sep;78(14):1517-1523. (PMID: 30229442) Pathogens. 2022 May 20;11(5):. (PMID: 35631120) Nature. 2021 Jul;595(7866):289-294. (PMID: 34194041) PLoS One. 2017 Feb 9;12(2):e0171826. (PMID: 28182750) Pharmaceuticals (Basel). 2019 Jul 30;12(3):. (PMID: 31366060) ACS Infect Dis. 2018 Aug 10;4(8):1264-1274. (PMID: 29998728) J Infect Dis. 2022 Sep 28;226(7):1267-1275. (PMID: 35512141) IDCases. 2018 Jun 30;13:e00414. (PMID: 30073148) Antimicrob Agents Chemother. 1997 Jan;41(1):91-4. (PMID: 8980761) Front Pharmacol. 2019 Oct 29;10:1222. (PMID: 31736746) J Exp Med. 2016 Jun 27;213(7):1307-18. (PMID: 27270894) N Engl J Med. 1995 Feb 2;332(5):298-303. (PMID: 7816065) J Infect Dis. 1997 May;175(5):1259-62. (PMID: 9129100) Antimicrob Agents Chemother. 2015 Oct;59(10):6151-60. (PMID: 26195527) Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0066221. (PMID: 34152821) J Infect Dis. 2019 Jul 2;220(3):442-447. (PMID: 31099380) Int J Parasitol. 2012 Aug;42(9):859-70. (PMID: 22846785) Transfusion. 2002 Nov;42(11):1482-7. (PMID: 12421222) N Engl J Med. 2019 Jan 17;380(3):229-241. (PMID: 30650326) Ann Intern Med. 1978 Feb;88(2):200-2. (PMID: 626449) Clin Infect Dis. 2010 Feb 1;50(3):381-6. (PMID: 20047477) Pathogens. 2022 Sep 15;11(9):. (PMID: 36145484) Ann Intern Med. 1993 Aug 15;119(4):284-90. (PMID: 8328736) Int J Parasitol. 2000 Nov;30(12-13):1323-37. (PMID: 11113258) Trends Parasitol. 2007 Dec;23(12):605-10. (PMID: 17988944) Bio Protoc. 2022 Nov 20;12(22):. (PMID: 36620533) J Wildl Dis. 2006 Apr;42(2):375-80. (PMID: 16870860) J Biol Chem. 2018 Dec 28;293(52):19974-19981. (PMID: 30463941) N Engl J Med. 2012 Jun 21;366(25):2397-407. (PMID: 22716978) Emerg Infect Dis. 2018 Aug;24(8):. (PMID: 30016254) Cell Death Discov. 2020 Oct 27;6:110. (PMID: 33133645) Clin Infect Dis. 2023 Feb 18;76(4):741-744. (PMID: 35684960) Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0020421. (PMID: 33941516) SAGE Open Med Case Rep. 2017 Aug 29;5:2050313X17725645. (PMID: 28890784) MMWR Morb Mortal Wkly Rep. 2019 Nov 22;68(46):1062-1068. (PMID: 31751320) Clin Infect Dis. 2021 Jan 27;72(2):185-189. (PMID: 33501959) Nat Microbiol. 2023 May;8(5):845-859. (PMID: 37055610) Parasit Vectors. 2020 Jul 20;13(1):362. (PMID: 32690081) IDCases. 2022 Feb 25;27:e01460. (PMID: 35242564) Emerg Infect Dis. 2018 Aug;24(8):1588-1589. (PMID: 30016247) Malar J. 2017 May 19;16(1):209. (PMID: 28526056) |
| معلومات مُعتمدة: | R44 AI136118 United States AI NIAID NIH HHS; AI123321 United States NH NIH HHS; R01 AI153100 United States AI NIAID NIH HHS; R01 AI123321 United States AI NIAID NIH HHS; R01 AI152220 United States AI NIAID NIH HHS; R43 AI136118 United States AI NIAID NIH HHS; R01 AI138139 United States AI NIAID NIH HHS |
| فهرسة مساهمة: | Keywords: Babesia MO1; Babesia divergens; Babesia duncani; Babesia microti; Plasmodium falciparum; erythrocyte; human babesiosis; parasite; sterile immunity; tafenoquine |
| المشرفين على المادة: | Y883P1Z2LT (Atovaquone) 262P8GS9L9 (tafenoquine) 0 (Aminoquinolines) |
| تواريخ الأحداث: | Date Created: 20240103 Date Completed: 20240115 Latest Revision: 20240716 |
| رمز التحديث: | 20240716 |
| مُعرف محوري في PubMed: | PMC10786256 |
| DOI: | 10.1093/infdis/jiad315 |
| PMID: | 38169301 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1537-6613 |
|---|---|
| DOI: | 10.1093/infdis/jiad315 |